Shanghai Shyndec Pharmaceutical Co Ltd (600420) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Shyndec Pharmaceutical Co Ltd (600420) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥486.04 Million ≈ $71.12 Million USD) by net assets (CN¥15.70 Billion ≈ $2.30 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shanghai Shyndec Pharmaceutical Co Ltd balance sheet quality to measure how much of total assets are equity-financed.
Shanghai Shyndec Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Shanghai Shyndec Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 600420 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Shanghai Shyndec Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Shyndec Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zen Technologies Limited
NSE:ZENTEC
|
-0.079x |
|
Xinhuanet Co Ltd
SHG:603888
|
0.034x |
|
Jiangsu Linyang Energy Co Ltd
SHG:601222
|
0.021x |
|
YOUZU Interactive Co Ltd
SHE:002174
|
0.007x |
|
OliX PharmaceuticalsInc
KQ:226950
|
-0.081x |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
0.061x |
|
Dime Community Bancshares, Inc.
NYSE:DCOM
|
0.032x |
|
Kirloskar Brothers Limited
NSE:KIRLOSBROS
|
0.048x |
Annual Cash Flow Conversion Efficiency for Shanghai Shyndec Pharmaceutical Co Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Shyndec Pharmaceutical Co Ltd from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Shanghai Shyndec Pharmaceutical Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥34.93 Billion ≈ $5.11 Billion |
CN¥1.70 Billion ≈ $248.48 Million |
0.049x | -66.98% |
| 2024-12-31 | CN¥15.32 Billion ≈ $2.24 Billion |
CN¥2.26 Billion ≈ $330.12 Million |
0.147x | +22.71% |
| 2023-12-31 | CN¥14.34 Billion ≈ $2.10 Billion |
CN¥1.72 Billion ≈ $251.74 Million |
0.120x | -48.94% |
| 2022-12-31 | CN¥12.15 Billion ≈ $1.78 Billion |
CN¥2.86 Billion ≈ $417.87 Million |
0.235x | +45.07% |
| 2021-12-31 | CN¥10.37 Billion ≈ $1.52 Billion |
CN¥1.68 Billion ≈ $245.79 Million |
0.162x | +1.94% |
| 2020-12-31 | CN¥9.82 Billion ≈ $1.44 Billion |
CN¥1.56 Billion ≈ $228.30 Million |
0.159x | +15.13% |
| 2019-12-31 | CN¥9.20 Billion ≈ $1.35 Billion |
CN¥1.27 Billion ≈ $185.86 Million |
0.138x | -30.19% |
| 2018-12-31 | CN¥8.44 Billion ≈ $1.24 Billion |
CN¥1.67 Billion ≈ $244.25 Million |
0.198x | -34.68% |
| 2017-12-31 | CN¥7.65 Billion ≈ $1.12 Billion |
CN¥2.31 Billion ≈ $338.69 Million |
0.303x | +150.41% |
| 2016-12-31 | CN¥6.94 Billion ≈ $1.02 Billion |
CN¥838.58 Million ≈ $122.71 Million |
0.121x | -14.06% |
| 2015-12-31 | CN¥1.61 Billion ≈ $235.83 Million |
CN¥226.65 Million ≈ $33.17 Million |
0.141x | -24.27% |
| 2014-12-31 | CN¥1.39 Billion ≈ $203.72 Million |
CN¥258.51 Million ≈ $37.83 Million |
0.186x | +18.60% |
| 2013-12-31 | CN¥1.33 Billion ≈ $193.92 Million |
CN¥207.50 Million ≈ $30.36 Million |
0.157x | -3.62% |
| 2012-12-31 | CN¥1.19 Billion ≈ $174.21 Million |
CN¥193.41 Million ≈ $28.30 Million |
0.162x | +13.10% |
| 2011-12-31 | CN¥947.63 Million ≈ $138.67 Million |
CN¥136.12 Million ≈ $19.92 Million |
0.144x | +4.53% |
| 2010-12-31 | CN¥837.59 Million ≈ $122.57 Million |
CN¥115.11 Million ≈ $16.84 Million |
0.137x | +0.63% |
| 2009-12-31 | CN¥713.46 Million ≈ $104.40 Million |
CN¥97.43 Million ≈ $14.26 Million |
0.137x | +48.57% |
| 2008-12-31 | CN¥631.47 Million ≈ $92.40 Million |
CN¥58.04 Million ≈ $8.49 Million |
0.092x | -33.63% |
| 2007-12-31 | CN¥594.29 Million ≈ $86.96 Million |
CN¥82.31 Million ≈ $12.04 Million |
0.138x | -3.74% |
| 2006-12-31 | CN¥511.49 Million ≈ $74.85 Million |
CN¥73.60 Million ≈ $10.77 Million |
0.144x | +19.00% |
| 2005-12-31 | CN¥478.84 Million ≈ $70.07 Million |
CN¥57.90 Million ≈ $8.47 Million |
0.121x | +213.99% |
| 2004-12-31 | CN¥441.88 Million ≈ $64.66 Million |
CN¥17.02 Million ≈ $2.49 Million |
0.039x | -- |
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and… Read more